Abatacept Biosimilar - Shilpa Biologicals
Alternative Names: SBDM-04Latest Information Update: 23 Dec 2022
At a glance
- Originator Shilpa Biologicals
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoglobulin fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins; Skin disorder therapies; Urologics
- Mechanism of Action T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Juvenile rheumatoid arthritis; Rheumatoid arthritis
Most Recent Events
- 29 Nov 2022 Preclinical trials in Juvenile rheumatoid arthritis in India (Parenteral) before November 2022 (Shilpa Biologicals pipeline, November 2022)
- 29 Nov 2022 Preclinical trials in Rheumatoid arthritis in India (Parenteral) before November 2022 (Shilpa Biologicals pipeline, November 2022)